3D Dynamic Contrast-Enhanced US for Monitoring Chemotherapy of Liver Metastasis

3D 动态对比增强超声用于监测肝转移化疗

基本信息

批准号：
9252422
负责人：
Dimitre Hristov Hristov
金额：
$ 25.29万
依托单位：
STANFORD UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-04-01 至 2019-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9252422
关键词：
Address Adverse effects Anatomy Angiogenesis Inhibitors Applications Grants Area Biological Markers Blood Vessels Blood Volume Blood flow Cancer Patient Chemotherapy-Oncologic Procedure Clinical Clinical Research Clinical Trials Colon Carcinoma Colorectal Colorectal Adenocarcinoma Colorectal Cancer Cytostatics Data Data Set Development Dimensions Electromagnetics Evaluation Excision Foundations Future Goals Gold Healthcare Histology Human Image Imagery Imaging Techniques Imaging technology Immunofluorescence Immunologic Injection of therapeutic agent Intravenous Lesion Liver Malignant Neoplasms Maps Metastatic Neoplasm to the Liver Methods Microbubbles Modality Monitor Morbidity - disease rate Motion Mus Neoplasm Metastasis Newly Diagnosed Oncologist Operative Surgical Procedures Organ Patient Care Patients Perfusion Phase Primary Neoplasm Progression-Free Survivals Public Health Radiation Reference Standards Reporting Reproducibility Research Research Project Grants Resources Sampling Errors Savings Scanning Site Solid Neoplasm Techniques Technology Therapeutic Agents Time Tissues Transducers Translating Tumor Volume Ultrasonic Transducer Ultrasonography X-Ray Computed Tomography Xenograft procedure abdominal CT anatomic imaging cancer therapy cancer type chemotherapy clinical application clinical imaging contrast enhanced cost cytotoxic effective therapy experimental study follow-up imaging approach imaging modality innovation intravenous administration molecular drug target mouse model non-invasive imaging novel perfusion imaging portability pre-clinical preclinical study predicting response predictive of treatment response prevent prospective public health relevance response treatment response tumor tumor heterogeneity two-dimensional

项目摘要

DESCRIPTION (provided by applicant): The ability to non-invasively predict which cancer patients will respond to chemotherapy will have significant implications for patient care and public health with the potential to spare non-responding patients the high morbidity and cost associated with these treatments. Therefore, novel non-invasive imaging technologies to allow both prediction and/or early evaluation of treatment response are critically needed. Due to its wide accessibility, lack of radiation, relatively low cost, and excellent visualization of the live, ultrasound perfusion imaging following intravenous administration of contrast microbubbles is a promising new functional modality for assessing tissue perfusion of liver metastases, the most common site of metastases in patients with colorectal cancer. However, current two-dimensional dynamic contrast-enhanced ultrasound (DCE-US), covering only a small fraction of the tumor volume, is fundamentally limited in quantification by the three-dimensional (3D) heterogeneity of tumor perfusion, resulting in consecutive sampling errors with substantial over- or underestimation of treatment response on DCE-US imaging. These limitations could be overcome by a novel 3D DCE-US imaging approach combining innovative matrix array transducer technology with real-time electromagnetic tracking to provide motion-compensated, accurate quantitative and volumetric assessment of tissue perfusion of liver metastases. Our overall goal is to assess 3D DCE-US reproducibility in patients with colorectal liver metastases and to evaluate its ability to predict treatment response. In 50 patients with newly diagnosed liver metastases from low grade colorectal adenocarcinoma, the reproducibility of tracking-assisted 3D DCE-US will be assessed by using a disruption-replenishment DCE-US technique which we had validated in previous preclinical experiments in human colon cancer xenografts in mice. Baseline and early changes of tumor perfusion parameters (obtained before and at 2-3 weeks after the initiation of chemotherapy) will then be correlated to the following endpoints: local treatment response, progression free survival, and histology. Treatment response as defined on abdominal CT scans acquired at 2 months following treatment initiation will be determined using RECIST 1.1 reporting as reference standard. Baseline values and early changes in perfusion parameters will be correlated with CT findings and with histology in patients undergoing surgical liver metastasis resection.

描述（由适用提供）：非侵入性预测哪些癌症患者对化学疗法的反应的能力将对患者护理和公共卫生产生重大影响，并有可能避免非应答患者具有与这些治疗相关的高发病率和成本。因此，非常需要进行新颖的非侵入性成像技术，以允许对治疗反应进行预测和/或早期评估。由于其广泛的可访问性，缺乏辐射，相对低成本以及对现场的极好可视化，在静脉内给予对比微泡后，超声灌注成像是一种有望评估肝脏转移组织的组织灌注的新功能模态，这是结直肠癌患者转移的最常见部位。然而，当前的二维动态对比增强超声（DCE-US）仅覆盖肿瘤体积的一小部分，从根本上限制了肿瘤灌注的三维（3D）异质性的数量，导致对DCE-IS Imaging dce-Is Imaging的实质性过度或潜在的治疗响应的连续采样。可以通过一种新型的3D DCE-US成像方法来克服这些局限性，该方法将创新的矩阵阵列换能器技术与实时电磁跟踪结合在一起，以提供组织灌注的运动补偿，准确的定量和体积评估我们的整体目标是评估3D DCE - US重新制作能力，以评估其能力响应的能力，以评估其能力。在50名来自低级彩色腺癌的新诊断肝转移的患者中，将通过使用颠覆性的DCE-US技术来评估跟踪辅助3D DCE-US的可重复性，我们在以前的抗蛋白结肠癌Xenograpts中在小鼠中的先前重蛋白实验中进行了验证。然后，肿瘤灌注参数的基线和早期变化（在化学疗法倡议后2-3周获得）将与以下终点相关：局部治疗反应，无进展生存率和组织学。在治疗计划后2个月获得的腹部CT扫描定义的治疗反应将使用Recist 1.1报告作为参考标准。在接受手术肝转移切除的患者中，基线值和灌注参数的早期变化将与CT发现和组织学相关。